Redeye

Redeye updates on Gentoo Media ahead of Q1-results (due 21 May) where we expect improved EBITDA YoY supported by cost savings, while we expect the company to reiterate its full year guidance suggesting further strengthening of the results in the coming quarters. $G2M redeye.se/research/11670…

Redeye har intervjuat Transtemas vd Jonas Rigner och CFO Tobias Martinsson om det första kvartalet samt hur de olika projekten för stärkt lönsamhet har utvecklats. $TRANS redeye.se/research/11669…

Redeye har interviewed Johan Emilsson, the CEO of Sprint Bioscience, to discuss the company's Q1 progress, the outlook for its pipeline and the growing attention the company has attracted following the TREX1 licensing deal with Gilead. $SPRINT redeye.se/research/11669…

Redeye provides a research update following the Q1 report published by Alzinova earlier today. $ALZ redeye.se/research/11625…

Redeye comments on Camurus' Q1 report 2026, which was below our estimates due to lower revenues from Buvidal and Brixadi. $CAMX redeye.se/research/11663…

Redeye provides a research update following the Q1 report published by Cinclus earlier today. $CINPHA redeye.se/research/11623…

Redeye har intervjuat Oncopeptides vd, Sofia Heigis, om Q1 och ansökan om bredare indikation. $ONCO redeye.se/research/11669…

Redeye comments on Ascelia's Q1 report and recent development in the company. $ACE redeye.se/research/11664…

Redeye comments on Siljansvik delivering a strong Q1 report with improved earnings across all major holdings and continued NAV growth. $SIVI redeye.se/research/11668…

Redeye considers AAC’s Q1 report to be on the soft side of our expectations, with -8% y/y growth and negative EBITDA. $AAC redeye.se/research/11667…

Redeye comments on Fable Media Group’s Q1 2026 results, which came in below our estimates on both revenue and profitability, though the miss does not alter our investment thesis. $FABLE redeye.se/research/11639…

Redeye is LIVE with IDL Diagnostics! Management of the company present the quarterly report followed by a Q&A. Tune in: redeye.se/events/1143814…

Redeye provides its first take on Oncopeptides' Q1 report 2026. Sales grew 37% versus Q4 2025. $ONCO redeye.se/research/11666…

Redeye retains its positive view of Transtema despite a softer-than-expected Q1. $TRANS redeye.se/research/11666…

Redeye returns with an update following SciBase Holding’s Q1 report, which largely met our expectations. $SCIB redeye.se/research/11664…

Redeye provides an update following CSG’s Q4 2025/2026 report, which showed sales above our estimates but weaker EBIT, mainly due to elevated development costs and restructuring-related items. $COFFEE redeye.se/research/11667…

Redeye updates on Better Collective ahead of Q1-results (due 20 May after market close) where we expect the company to return to organic growth, albeit somewhat tempered by headwind from a soft sportswin margin in the quarter. $BETCO redeye.se/research/11667…

Redeye initiates coverage of InCoax, a niche market leader in network equipment specialized in utilizing existing coax-networks in buildings, offering a unique and attractive business case for internet service providers. $INCOAX redeye.se/research/11667…

Redeye provides an update following CLS’s Q1 2026 report. The report was broadly in line with our expectations, with the weak sales primarily explained by ongoing partner discussions during the quarter. $CLS redeye.se/research/11664…

Redeye comments on Moberg Pharma delivering a solid Q1 2026 report with sales exceeding expectations and a significantly stronger EBIT than forecast, driven by disciplined cost management and a one-off boost from FX gains. $MOB redeye.se/research/11665…